Introducing Maestro: The First AI-Infused Supply Chain Orchestration Platform from Kinaxis
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today introduced the Kinaxis Maestro™ platform, the only AI-infused supply chain orchestration platform with a powerful combination of proprietary computational technologies and techniques that provides full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. An evolution of the company’s flagship platform, RapidResponse, Maestro incorporates new, modern AI technologies to help teams move faster and smarter to master the complexities of today’s modern supply chains.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240618998841/en/
Kinaxis announced its AI-infused orchestration platform, Maestro, at global supply chain conference Kinexions in Miami, FL. (Graphic: Business Wire)
The Maestro platform comprises three layers: a supply chain data fabric connecting internal and external data sources into a single source of truth, an always-on intelligence engine that delivers real-time insights, predictions and adaptive solutions, and a seamless user interface, enabling business leaders to make faster and more valuable decisions than ever before, from anywhere and from any device. For example, in response to skyrocketing demand of a new EV following a high-profile celebrity endorsement, an automaker concerned about component shortages might ask ‘How do I prevent a stockout?’. Without missing a beat, Maestro’s generative AI-powered intelligent assistant will provide guidance based on supply chain best practices to ensure disruptions are absorbed and managed in real-time.
"It’s a challenging time to be a business leader in supply chain. Managing the complexities of global and regional supply chains, balancing agility, cost reduction, and sustainability, and handling a steady stream of geopolitical, economic, and environmental disruptions amid a data explosion,” said Andrew Bell, chief product officer at Kinaxis. “Yet, with the right technologies, there's unprecedented potential to resolve this complexity and master uncertainty. Maestro provides total supply chain transparency, aligns advanced technology with specific challenges, and integrates diverse data—from social media sentiment to government regulations—bringing clarity to chaos so business leaders can sleep soundly at night."
National Instruments took part in the beta phase of Maestro’s generative AI capabilities and Ed Scott, chief program manager said, “From the moment our team deployed Maestro’s intelligent assistant, it was clear it would be a gamechanger. We’ve been able to significantly cut down on the amount of time it takes for users to maximize the value of the platform and we are eager to build on these initial successes as Kinaxis continues to roll out the full breadth of its AI capabilities.”
What makes Maestro different:
- Seamless synchronization. Unmatched agility – Gain a comprehensive, always-on digital view of your supply chain, ensuring continuous synchronization of data, people, and processes for unmatched agility.
- Be ready. Whatever happens – Predict future scenarios with smart modeling and make informed decisions quickly to confidently navigate uncertainties and drive success.
- Strike the perfect balance of accuracy, efficiency, and speed – Fuse machine learning, heuristics and optimization for unparalleled problem-solving, keeping your supply chain at the cutting edge.
- Take your productivity to the next level – Automate routine tasks with AI and predictive algorithms, allowing you to focus on strategic priorities and boost productivity.
- Empower your people to do more with more – Empower your teams with an intuitive tool that simplifies complex tasks and enhances efficiency, enabling greater satisfaction and achievement.
- No data wrangling required – Achieve faster time-to-value by easily ingesting data from various sources without the need for schema definition; just drag, drop, and go.
Global market intelligence firm IDC previewed Maestro prior to launch and Eric Thompson, IDC Worldwide Supply Chain Planning Research Director, noted, “IDC has been discussing end-to-end supply chain integration, and Kinaxis is making moves forward with Maestro. The platform’s progress in combining end-to-end concurrency with smart, user-friendly AI, is a promising step in supply chain orchestration.”
From building the first in-memory material requirements planning (MRP) engine in the 1980s to adopting a SaaS model years before its peers and launching the first cloud-friendly planning platform in the 2000s, Kinaxis has been at the forefront of every major technological innovation within the supply chain industry for the past four decades. The company has consistently prioritized designing products to meet the evolving needs of its customers, focusing on pillars of connectivity, intelligence, adaptability, and user-friendliness. In the previous five years alone, the company’s patent portfolio has grown by more than 500%, with over half of those patents awarded for AI and ML-based innovations.
Celebrating its 40th anniversary in 2024, Kinaxis helps companies that supply the agricultural industry with 40% of the world’s tractors, that keep more than 110 billion teeth clean each year, and that ensure more than 35 million pets are fed nutritious meals each year.
About Kinaxis
Kinaxis is a global leader in modern supply chain orchestration. We serve supply chains and the people who manage them in service of humanity. Our software is trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. We combine our patented concurrency technique with a human-centered approach to AI to empower businesses of all sizes to manage their end-to-end supply chain network, from multi-year strategic planning through down-to-the-second execution and last-mile delivery. For more news and information, please visit kinaxis.com or follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240618998841/en/
Contacts
Media Relations
Jaime Cook | Kinaxis
jcook@kinaxis.com289-552-4640
Investor Relations
Rick Wadsworth | Kinaxis
rwadsworth@kinaxis.com
613-907-7613
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom